Although KRAS gene mutation is related to metabolic reprogramming in cancer cells [20, 26] or in genetically engineered mouse models [33, 34], it’s biological effects on metabolic reprogramming in human cells as early events in PDAC carcinogenesis are unclear. The gene discussed is KRAS; the disease is cancer.